Phase I and pharmacokinetic study of Yondelis(TM) (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

Author： Twelves C.   Hoekman K.   Bowman A.   Vermorken J.B.   Anthoney A.   Smyth J.   van Kesteren C.   Beijnen J.H.   Uiters J.   Wanders J.   Gomez J.   Guzman C.   Jimeno J.   Hanauske A.   for the New Drug Development Group of the EORTC  

Publisher： Elsevier

ISSN： 0959-8049

Source： European Journal of Cancer, Vol.39, Iss.13, 2003-09, pp. : 1842-1851

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours

By Awada A.   Thodtmann R.   Piccart M.J.   Wanders J.   Schrijvers A.H.G.J.   Von Broen I.-M.   Hanauske A.R.  

European Journal of Cancer, Vol. 39, Iss. 6, 2003-04 ,pp. : 742-747

Elsevier

Access to resources Recommend Favorite

Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG)

By Terret C.   Zanetta S.   Roche H.   Schellens J.H.M.   Faber M.N.   Wanders J.   Ravic M.   Droz J.P.  

European Journal of Cancer, Vol. 39, Iss. 8, 2003-05 ,pp. : 1097-1104

Elsevier

Access to resources Recommend Favorite

Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer

By Beumer Jan   Rademaker-Lakhai Jeany   Rosing Hilde   Hillebrand Michel   Bosch Tessa   Lopez-Lazaro Luis   Schellens Jan   Beijnen Jos  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 6, 2007-06 ,pp. : 825-837

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer

By Zhu Andrew   Clark Jeffrey   Ryan David   Meyerhardt Jeffrey   Enzinger Peter   Earle Craig   Fuchs Charles   Regan Eileen   Anbe Hiroshi   Houghton Michele   Zhang Joshua   Urrea Peter   Kulke Matthew  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 3, 2007-03 ,pp. : 285-293

Springer Publishing Company

Access to resources Recommend Favorite

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action

By Erba E.   Bergamaschi D.   Bassano L.   Damia G.   Ronzoni S.   Faircloth G.T.   D'Incalci M.  

European Journal of Cancer, Vol. 37, Iss. 1, 2001-01 ,pp. : 97-105

Elsevier

Access to resources Recommend Favorite